Fluzoparib plus hormone therapy after surgery for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18–70 and can do your trial visits (performance status 0–1).
- Your tumor tests show ER-positive and HER2-negative breast cancer, and it matches the SNF3 subtype on special pathology review.
- Your cancer is not metastatic: stage T2–4, any N from 0–3, and M0—after surgery.
- You started the study within 16 months of surgery, and your last non-hormone cancer treatment was within 12 weeks.
- Your blood counts and heart/liver/kidney function are adequate based on lab tests, and infections are controlled.
- You can take pills by mouth, and if you could become pregnant, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called fluzoparib (a PARP inhibitor) after surgery for early breast cancer in people with specific gene mutations that affect DNA repair. The goal is to see if this drug lowers the chance of cancer coming back.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapies (pertuzumab and trastuzumab) and hormone therapy (palbociclib and exemestane) given before surgery for triple-positive breast cancer. The goal is to see if this package effectively shrinks the tumor and improves outcomes.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.